Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 15, 2025
Finance
Orum, Aardvark IPOs trade in opposite directions: Public Equity Report
Largest KOSDAQ biotech offering since 2022 goes to protein degradation company; San Diego metabolic play gets lukewarm NASDAQ reception
BioCentury | Oct 16, 2024
Discovery & Translation
Science Spotlight: Better genomic predictors for Black AML patients
BioCentury’s roundup of translational innovations also includes a method for continuous base edits, plus updates from Monte Rosa and ImCheck
BioCentury | Oct 4, 2024
Finance
Phase I biotechs Septerna, Orum bolster IPO queue
BioCentury’s Public Equity Report also features Caliway’s IPO, Biohaven’s $287.5M follow-on
BioCentury | Mar 30, 2024
Discovery & Translation
Combining ADCs with protein degraders could widen the therapeutic windows of both
Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge
BioCentury | Nov 6, 2023
Deals
Nov. 6 Quick Takes: BMS buying Orum’s protein degrader
Plus: Ventyx terminates VTX958 in plaque psoriasis, psoriatic arthritis and updates from Celldex, MoonLake and ProfoundBio
BioCentury | Nov 11, 2022
Product Development
Molecular glue degraders: moving beyond IMiDs
Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
Items per page:
1 - 7 of 7